Eidos Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Eidos Therapeutics's estimated annual revenue is currently $4.9M per year.
- Eidos Therapeutics's estimated revenue per employee is $77,500
- Eidos Therapeutics's total funding is $64M.
Employee Data
- Eidos Therapeutics has 63 Employees.
- Eidos Therapeutics grew their employee count by -14% last year.
Eidos Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | SVP, Regulatory Affairs, BridgeBio Cardiorenal | Reveal Email/Phone |
3 | SVP, Corporate Development | Reveal Email/Phone |
4 | VP, Quality and Compliance | Reveal Email/Phone |
5 | VP Clinical Development | Reveal Email/Phone |
6 | Director, Analytical Chemistry | Reveal Email/Phone |
7 | Director, Drug Product | Reveal Email/Phone |
8 | Director Quality Assurance | Reveal Email/Phone |
9 | Director, QA | Reveal Email/Phone |
10 | Associate Director, Professional Services | Reveal Email/Phone |
Eidos Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Eidos Therapeutics?
Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. Eidos seeks to treat this well-defined family of diseases at their collective source by stabilizing TTR.
keywords:N/A
$64M
Total Funding
63
Number of Employees
$4.9M
Revenue (est)
-14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Eidos Therapeutics News
... Eidos Montreal (EIDX) - Get Eidos Therapeutics Inc Report was the first big budget studio to get on board in October 2021.
On January 26, 2021, the company completed a merger with Eidos Therapeutics. BridgeBio stated at the time that it allowed BridgeBio to...
Eidos trades publicly on the Nasdaq, and its shares fell 6.5 percent Monday morning following the news, remaining down 3.1 percent Tuesday afternoon. BridgeBio’s shares were up 2 percent. The subsidiary, which is headquartered in San Francisco, is developing the drug AG10, which is currently in ...
Eidos Therapeutics, Inc., a San Francisco, CA-based clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), raised $64.0m Series B financing. The round, which brings the total capital raised to approximately $91.0m, was led by RA ...
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $13.9M | 63 | -15% | $31M |
#2 | $13.9M | 63 | 29% | $77.7M |
#3 | $5.8M | 63 | N/A | N/A |
#4 | $8.2M | 63 | N/A | N/A |
#5 | $7.9M | 63 | 50% | $33.6M |